Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
    • State Disclosures
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Cocaine Intoxication
      • Migraine
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Mpox (Monkey Pox)
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-801
      • TNX-1800
      • TNX-4200 CD45
    • Rare Disease
      • TNX-2900
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • Investor Presentations
    • Scientific Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
      • Investor Presentations
      • Scientific Presentations
      • Program Specific Presentations
      • Fact Sheet
      • Conference Materials
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Multimedia

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Form 8937
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19
Sep 24, 2020

Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19

Bringing new medicines to market despite subjective endpoints, Seth Lederman
Aug 11, 2020

Bringing new medicines to market despite subjective endpoints, Seth Lederman

Dr. Seth Lederman presents a vaccine tutorial covering the challenges and opportunities of developing a vaccine for COVID-19
Aug 11, 2020

Dr. Seth Lederman presents a vaccine tutorial covering the challenges and opportunities of developing a vaccine for COVID-19

Dr. Seth Lederman interviewed by Jane King on New to the Street to discuss Tonix’s portfolio of product candidates to fight COVID-19
Jul 8, 2020

Dr. Seth Lederman interviewed by Jane King on New to the Street to discuss Tonix’s portfolio of product candidates to fight COVID-19

Dr. Seth Lederman interviewed on Bloomberg TV to discuss the goals & timeline for development of TNX-1800, Tonix’s live replicating COVID-19 vaccine candidate.
Jul 8, 2020

Dr. Seth Lederman interviewed on Bloomberg TV to discuss the goals & timeline for development of TNX-1800, Tonix’s live replicating COVID-19 vaccine candidate.

Seth Lederman interviewed by KWTX’s Haley Vyrostek about Tonix’s partnership with Fujifilm Diosynth to manufacture and develop their COVID-19 vaccine candidate, TNX-1800, for clinical trial supply.
Jun 17, 2020

Seth Lederman interviewed by KWTX’s Haley Vyrostek about Tonix’s partnership with Fujifilm Diosynth to manufacture and develop their COVID-19 vaccine candidate, TNX-1800, for clinical trial supply.

Efforts to Manufacture a COVID-19 Vaccine (Podcast)
Jun 9, 2020

Efforts to Manufacture a COVID-19 Vaccine (Podcast)

New York City based pharmaceutical company chooses College Station to manufacture possible coronavirus vaccine
Jun 1, 2020

New York City based pharmaceutical company chooses College Station to manufacture possible coronavirus vaccine

Tonix Pharmaceuticals Discusses Developing COVID-19 Vaccine in Collaboration with Southern Research
May 28, 2020

Tonix Pharmaceuticals Discusses Developing COVID-19 Vaccine in Collaboration with Southern Research

MicroCap Investing Workshop: Potential Solutions for Addressing the Coronavirus Pandemic
Apr 21, 2020

MicroCap Investing Workshop: Potential Solutions for Addressing the Coronavirus Pandemic

Tonix Pharmaceuticals (NASDAQ: TNXP) | CEO Seth Lederman | 'Innovators with Jane King'
Feb 3, 2020

Tonix Pharmaceuticals (NASDAQ: TNXP) | CEO Seth Lederman | 'Innovators with Jane King'

rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2025 Tonix Pharmaceuticals Holding Corp.